Polar Asset Management Partners Inc. Tricida, Inc. Transaction History

Polar Asset Management Partners Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $1.98 Million - $3.17 Million	233,000 New	233,000 $2.44 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $1.18 Million - $1.91 Million	-161,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $676,685 - $1.54 Million	161,500 New	161,500 $1.54 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Polar Asset Management Partners Inc., based on Form 13F filings with the SEC.

Stay updated on Polar Asset Management Partners Inc. with notifications on news.